• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

DNA 损伤反应与癌症治疗。

The DNA damage response and cancer therapy.

机构信息

The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK.

出版信息

Nature. 2012 Jan 18;481(7381):287-94. doi: 10.1038/nature10760.

DOI:10.1038/nature10760
PMID:22258607
Abstract

Genomic instability is one of the most pervasive characteristics of tumour cells and is probably the combined effect of DNA damage, tumour-specific DNA repair defects, and a failure to stop or stall the cell cycle before the damaged DNA is passed on to daughter cells. Although these processes drive genomic instability and ultimately the disease process, they also provide therapeutic opportunities. A better understanding of the cellular response to DNA damage will not only inform our knowledge of cancer development but also help to refine the classification as well as the treatment of the disease.

摘要

基因组不稳定性是肿瘤细胞最普遍的特征之一,可能是 DNA 损伤、肿瘤特异性 DNA 修复缺陷以及在受损 DNA 传递给子细胞之前无法停止或停滞细胞周期的综合作用。尽管这些过程驱动了基因组不稳定性,并最终导致了疾病进程,但它们也提供了治疗机会。更好地了解细胞对 DNA 损伤的反应不仅将丰富我们对癌症发展的认识,还有助于完善疾病的分类和治疗。

相似文献

1
The DNA damage response and cancer therapy.DNA 损伤反应与癌症治疗。
Nature. 2012 Jan 18;481(7381):287-94. doi: 10.1038/nature10760.
2
PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.临床使用的PARP抑制剂会在正常人类细胞中诱导基因组不稳定。
PLoS One. 2016 Jul 18;11(7):e0159341. doi: 10.1371/journal.pone.0159341. eCollection 2016.
3
Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.聚腺苷二磷酸核糖聚合酶(PARPs)作为治疗某些癌症的治疗靶点。
Expert Opin Ther Targets. 2019 Sep;23(9):773-785. doi: 10.1080/14728222.2019.1654458. Epub 2019 Aug 13.
4
Strategies for targeting the DNA damage response for cancer therapeutics.针对癌症治疗的DNA损伤反应的靶向策略。
Chin J Cancer. 2012 Aug;31(8):359-63. doi: 10.5732/cjc.012.10087. Epub 2012 Jun 14.
5
Mitotic functions of poly(ADP-ribose) polymerases.聚(ADP-核糖)聚合酶的有丝分裂功能。
Biochem Pharmacol. 2019 Sep;167:33-43. doi: 10.1016/j.bcp.2019.03.028. Epub 2019 Mar 22.
6
The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer.赖氨酸特异性甲基转移酶 KMT2C/MLL3 调节癌症中的 DNA 修复成分。
EMBO Rep. 2019 Mar;20(3). doi: 10.15252/embr.201846821. Epub 2019 Jan 21.
7
DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.DNA损伤修复与聚(ADP-核糖)聚合酶抑制在癌症治疗中的新作用
Clin Ther. 2016 Jul;38(7):1577-88. doi: 10.1016/j.clinthera.2016.06.006. Epub 2016 Jun 29.
8
Targeting DNA repair in cancer: current state and novel approaches.针对癌症的 DNA 修复:现状与新方法。
Cell Mol Life Sci. 2020 Feb;77(4):677-703. doi: 10.1007/s00018-019-03299-8. Epub 2019 Oct 14.
9
Inhibition of poly(ADP-ribose) polymerase-1 by arsenite interferes with repair of oxidative DNA damage.亚砷酸盐对聚(ADP-核糖)聚合酶-1的抑制作用会干扰氧化性DNA损伤的修复。
J Biol Chem. 2009 Mar 13;284(11):6809-17. doi: 10.1074/jbc.M805566200. Epub 2008 Dec 3.
10
Poly(ADP-ribose) polymerase activity and inhibition in cancer.聚(ADP-核糖)聚合酶活性及其在癌症中的抑制作用。
Semin Cell Dev Biol. 2017 Mar;63:144-153. doi: 10.1016/j.semcdb.2017.01.007. Epub 2017 Jan 10.

引用本文的文献

1
Integrative multi-omics analysis and machine learning reveal the unique role of ASCC3 in combination with various immune-related genes in rectal adenocarcinoma.整合多组学分析和机器学习揭示了ASCC3与多种免疫相关基因联合在直肠腺癌中的独特作用。
Front Genet. 2025 Aug 13;16:1614946. doi: 10.3389/fgene.2025.1614946. eCollection 2025.
2
WTAP participates in the DNA damage response via an mA-FOXM1-dependent manner in hepatocellular carcinoma.在肝细胞癌中,WTAP通过一种依赖于mA-FOXM1的方式参与DNA损伤反应。
Cell Death Discov. 2025 Aug 22;11(1):397. doi: 10.1038/s41420-025-02639-x.
3
Genome-wide interaction study of physical activity and genetic susceptibility on colorectal cancer using UK biobank data.

本文引用的文献

1
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers.在乳腺癌个体化医学的道路上的绊脚石:PARP 抑制剂在 BRCA1/2 相关癌症中的应用。
Cancer Discov. 2011 Jun;1(1):29-34. doi: 10.1158/2159-8274.CD-11-0048. Epub 2011 Jun 1.
2
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.尼拉帕尼非选择性修饰肿瘤细胞中含半胱氨酸的蛋白质,而不是真正的 PARP 抑制剂。
Clin Cancer Res. 2012 Jan 15;18(2):510-23. doi: 10.1158/1078-0432.CCR-11-1973. Epub 2011 Nov 29.
3
Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements.
利用英国生物银行数据对体力活动与结直肠癌遗传易感性进行全基因组交互作用研究。
Sci Rep. 2025 Aug 18;15(1):30180. doi: 10.1038/s41598-025-13709-6.
4
Efficacy of NAMPT Inhibitors in Pancreatic Cancer After Stratification by MAP17 (PDZK1IP1) Levels.根据MAP17(PDZK1IP1)水平分层后,烟酰胺磷酸核糖转移酶(NAMPT)抑制剂在胰腺癌中的疗效。
Cancers (Basel). 2025 Aug 5;17(15):2575. doi: 10.3390/cancers17152575.
5
The impact of oxidative stress and the NRF2-KEAP1-ARE signaling pathway on anticancer drug resistance.氧化应激和NRF2-KEAP1-ARE信号通路对抗癌药物耐药性的影响。
Oncol Res. 2025 Jul 18;33(8):1819-1834. doi: 10.32604/or.2025.065755. eCollection 2025.
6
Response gene to complement 32 promotes tumorigenesis by mediating DNA damage repair and inhibits CD8+ T cells infiltration in diffuse large B-cell lymphoma.补体32反应基因通过介导DNA损伤修复促进肿瘤发生,并抑制弥漫性大B细胞淋巴瘤中CD8+ T细胞浸润。
Front Immunol. 2025 Jul 16;16:1591615. doi: 10.3389/fimmu.2025.1591615. eCollection 2025.
7
Targeting DNA Damage Response-Mediated Resistance in Non-Small Cell Lung Cancer: From Mechanistic Insights to Drug Development.靶向非小细胞肺癌中DNA损伤反应介导的耐药性:从机制洞察到药物开发
Curr Oncol. 2025 Jun 23;32(7):367. doi: 10.3390/curroncol32070367.
8
Bibliometric analysis of global research trends in pancreatic cancer immunotherapy.胰腺癌免疫治疗全球研究趋势的文献计量分析
Hum Vaccin Immunother. 2025 Dec;21(1):2538330. doi: 10.1080/21645515.2025.2538330. Epub 2025 Jul 24.
9
Breast carcinomas associated with microglandular adenosis are linked to germline alterations in homologous recombination-deficiency genes.与微腺性腺病相关的乳腺癌与同源重组缺陷基因的种系改变有关。
NPJ Breast Cancer. 2025 Jul 22;11(1):76. doi: 10.1038/s41523-025-00794-z.
10
Induction of cancer stem cells from mouse fibroblasts.从小鼠成纤维细胞诱导生成癌症干细胞。
Sci Rep. 2025 Jul 15;15(1):25489. doi: 10.1038/s41598-025-09686-5.
染色体灾难涉及复制机制,产生复杂的基因组重排。
Cell. 2011 Sep 16;146(6):889-903. doi: 10.1016/j.cell.2011.07.042.
4
Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer.BRCA2 缺陷型人胰腺癌细胞的全基因组分析。
PLoS One. 2011;6(7):e21639. doi: 10.1371/journal.pone.0021639. Epub 2011 Jul 5.
5
Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.切除 NSCLC 中 ERCC1 阴性与 ERCC1 阳性肿瘤的分子特征。
Clin Cancer Res. 2011 Sep 1;17(17):5562-72. doi: 10.1158/1078-0432.CCR-11-0790. Epub 2011 Jul 12.
6
Determinants and dynamics of genome accessibility.基因组可及性的决定因素和动态。
Nat Rev Genet. 2011 Jul 12;12(8):554-64. doi: 10.1038/nrg3017.
7
Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.鉴定和评价新型ATR 抑制剂 NU6027 在乳腺癌和卵巢癌细胞系中的作用。
Br J Cancer. 2011 Jul 26;105(3):372-81. doi: 10.1038/bjc.2011.243. Epub 2011 Jul 5.
8
Integrated genomic analyses of ovarian carcinoma.卵巢癌的综合基因组分析。
Nature. 2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166.
9
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.继发性体细胞突变恢复 BRCA1/2 预测遗传性卵巢癌的化疗耐药性。
J Clin Oncol. 2011 Aug 1;29(22):3008-15. doi: 10.1200/JCO.2010.34.2980. Epub 2011 Jun 27.
10
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.CDK1 活性受抑制使 BRCA 功能正常的癌症对 PARP 抑制剂敏感。
Nat Med. 2011 Jun 26;17(7):875-82. doi: 10.1038/nm.2377.